Drug Shortage Report for DALACIN C PHOSPHATE
Report ID | 146307 |
Drug Identification Number | 00260436 |
Brand name | DALACIN C PHOSPHATE |
Common or Proper name | DALACIN C PHOSPHATE |
Company Name | PFIZER CANADA ULC |
Market Status | MARKETED |
Active Ingredient(s) | CLINDAMYCIN |
Strength(s) | 150MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
Packaging size | 1 x 60mL |
ATC code | J01FF |
ATC description | MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | |
Actual start date | 2021-10-01 |
Estimated end date | |
Actual end date | 2021-10-13 |
Shortage status | Resolved |
Updated date | 2021-10-14 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v8 | 2021-10-14 | English | Compare |
v7 | 2021-10-13 | French | Compare |
v6 | 2021-10-13 | English | Compare |
v5 | 2021-10-02 | English | Compare |
v4 | 2021-10-01 | French | Compare |
v3 | 2021-10-01 | English | Compare |
v2 | 2021-09-28 | French | Compare |
v1 | 2021-09-28 | English | Compare |
Showing 1 to 8 of 8